- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Latest Pharmagenics News
Jul 17, 2013
Genzyme, PharmaGenics shareholders approve acquisition Jun 16, 1997, 4:03pm EDT Updated Jun 16, 1997, 4:03pm EDT //= $authorImg ?> Save Article Shareholders of Cambridge-based Genzyme Corp. and PharmaGenics Inc. voted to approve the acquisition of PharmaGenics by Genzyme in exchange for approximately 4 million shares, subject to adjustment, of a new Genzyme tracking stock, Genzyme Molecular Oncology. The transaction is expected to close shortly and is valued at approximately $28 million. PharmaGenics develops therapeutic products for cancer through the use of genomics technology. Want Boston news in your inbox? Sign up for our free email newsletters. Suggested Reading
Pharmagenics Frequently Asked Questions (FAQ)
Where is Pharmagenics's headquarters?
Pharmagenics's headquarters is located at 4 Pearl Court, Allendale.
What is Pharmagenics's latest funding round?
Pharmagenics's latest funding round is Acquired.
How much did Pharmagenics raise?
Pharmagenics raised a total of $5.03M.
Who are the investors of Pharmagenics?
Investors of Pharmagenics include Genzyme and Rho Ventures.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
